IN8bio, Inc.

Healthcare · Biotechnology · United States

Last price 0.9801 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.66M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinic...